Integrin β8 prevents pericyte-myofibroblast transition and renal fibrosis through inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney disease
Translational Research · 2024-03 · 265 · 36-50
DOI: 10.1016/j.trsl.2023.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2024-03. Verfasst von Yiling Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetic Nephropathies, Integrin beta Chains. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, National Natural Science Foundation of China.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is one of the leading causes to develop end-stage kidney disease worldwide. Pericytes are implicated in the development of tissue fibrosis. However, the underlying mechanisms of pericytes in DKD remain largely unknown. We isolated and cultured primary pericytes and rat mesangial cells (HBZY-1). Western blot and qRT-PCR analysis were used to explore the role and regulatory mechanism of Integrin β8/transforming growth factor beta 1 (TGF-β1) pathway. We also constructed pericyte-specific Integrin β8 knock-in mice as the research objects to determine the role of Integrin β8 in vivo. We discovered that reduced Integrin β8 expression was closely associated with pericyte transition in DKD. Overexpressed Integrin β8 in pericytes dramatically suppressed TGF-β1/TGF beta receptor 1 (TGFBR1)/Smad3 signaling pathway and protected glomerular endothelial cells (GECs) in vitro. In vivo, pericyte-specific Integrin β8 knock-in ameliorated pericyte transition, endothelium injury and renal fibrosis in STZ-induced diabetic mice. Mechanistically, Murine double minute 2 (MDM2) was found to increase the degradation of Integrin β8 and caused TGF-β1 release and activation. Knockdown MDM2 could partly reverse the decline of Integrin β8 and suppress pericytes transition. In conclusion, the present findings suggested that upregulated MDM2 expression contributes to the degradation of Integrin β8 and activation of TGF-β1/TGFBR1/Smad3 signaling pathway, which ultimately leads to pericyte transition during DKD progression. These results indicate MDM2/Integrin β8 might be considered as therapeutic targets for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
- 5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, D-68167 Mannheim, Germany.
- Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: drzhangchun@hust.edu.cn.
Förderung
- Deutsche Forschungsgemeinschaft
- National Natural Science Foundation of China
Zitieren
APA
Cao, Y., Su, H., Zeng, J., Xie, Y., Liu, Z., Liu, F., Qiu, Y., Yi, F., Lin, J., Hammes, H. P., & Zhang, C. (2024). Integrin β8 prevents pericyte-myofibroblast transition and renal fibrosis through inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney disease. Translational Research, 265, 36-50. https://doi.org/10.1016/j.trsl.2023.10.007
Vancouver
Cao Y, Su H, Zeng J, Xie Y, Liu Z, Liu F, et al. Integrin β8 prevents pericyte-myofibroblast transition and renal fibrosis through inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney disease. Translational Research. 2024;265:36-50. doi:10.1016/j.trsl.2023.10.007
BibTeX
@article{Cao2024,
author = {Cao, Yiling and Su, Hua and Zeng, Jieyu and Xie, Yaru and Liu, Zezhou and Liu, Feng and Qiu, Yang and Yi, Fan and Lin, Jihong and Hammes, Hans-Peter and Zhang, Chun},
title = {Integrin β8 prevents pericyte-myofibroblast transition and renal fibrosis through inhibiting the TGF-β1/TGFBR1/Smad3 pathway in diabetic kidney disease},
journal = {Translational Research},
year = {2024},
volume = {265},
pages = {36--50},
doi = {10.1016/j.trsl.2023.10.007}
}
EUVIMED